Severe necrotizing myopathy after COVID‐19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma.

Autor:	Blaise, M., Rocher, F., Spittler, H., Sanchez, A., Lanteri, E., Coco, L., Puma, A., Martel, A., Gonfrier, G., Passeron, T., Montaudié, H.
Předmět:	COVID-19 vaccines MELANOMA IPILIMUMAB DRUG side effects NIVOLUMAB MUSCLE diseases
Zdroj:	Journal of the European Academy of Dermatology & Venereology; Feb2022, Vol. 36 Issue 2, pe100-e102, 3p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text